- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02377752
A Study of Olaratumab in Japanese Participants With Advanced Cancer
A Phase 1 Study of Olaratumab in Japanese Patients With Advanced Soft Tissue Sarcoma or Advanced Solid Tumors
Přehled studie
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
-
Chuo-Ku, Japonsko, 104-0045
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
-
Koto-ku, Japonsko, 135-8550
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
-
Nagoya, Japonsko, 466-8560
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
-
Suita-shi, Japonsko, 565-0871
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Part A: Have histological or cytological evidence of a diagnosis of advanced or metastatic solid tumor, especially STS, which is not amenable to treatment with surgery or radiotherapy. Part B: Have histological or cytological evidence of a diagnosis of solid tumor that is advanced or metastatic.
- Have the presence of measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST).
- Have given written informed consent prior to any study-specific procedures.
- Have adequate organ and coagulation function
- Have an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of less than or equal to 1.
- Have discontinued previous treatments for cancer and recovered from the acute effects of therapy.
- (Part A only) Have a prestudy echocardiogram with an actual left ventricular ejection fraction greater than or equal to 50%, within 21 days prior to first dose of study medication.
- All participants agree to use a reliable method of birth control and to not donate sperm during the study and for at least 3 months following last dose of study drug.
Female participants:
- must either be women not of child-bearing potential due to surgical sterilization confirmed by medical history, or menopause or
- women of child-bearing potential who test negative for pregnancy within 7 days before the first dose of study drug based on serum or urine pregnancy test and agree not to breast feed during the study and for 3 months following the last dose of the study drug(s)
- Have an estimated life expectancy of more than or equal to 3 months in the judgment of the investigator.
Exclusion Criteria:
- Have received treatment within 21 days of the initial dose of study drug with an investigational product or non-approved use of a drug or device for non-cancer indications or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
- (Part A only) Have received prior treatment with doxorubicin, daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones
- (Part A only) Have received prior radiation therapy to the mediastinal/pericardial area.
- Have symptomatic central nervous system malignancy or metastasis. Participants with treated central nervous system (CNS) metastases are eligible for this study if they are not currently receiving corticosteroids and/or anticonvulsants, and their disease is asymptomatic and radiographically stable for at least 60 days.
- Have an elective or a planned major surgery to be performed during the course of the study.
- Have an uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure greater than class II of the New York Heart Association guideline, severe myocardial insufficiency, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Have unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 6 months prior to study entry.
- Have a known allergy to any of the treatment components.
- Have a history of allergic reactions attributed to compounds of chemical or biologic composition similar to that of olaratumab.
- Have a known active fungal, bacterial, and/or known viral infection
- Have a corrected QT interval of greater than 470 milliseconds (msec) on screening electrocardiogram (ECG)
- Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Part A cohort 1: Olaratumab+Doxorubicin
15 milligram per kilogram (mg/kg) of olaratumab administered intravenously (IV) on Day 1 and Day 8, and 25 milligram per square meter (mg/m2) of doxorubicin administered IV on Day 1, Day 2, and Day 3 every 21-day cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met . |
Podáno IV
Ostatní jména:
Podáno IV
|
Experimentální: Part A cohort 2: Olaratumab+Doxorubicin
15 mg/kg of olaratumab administered IV on Day 1 and Day 8, and 75 mg/m2 of doxorubicin administered IV on Day 1 every 21 day-cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles.
Participants may continue to receive treatment until discontinuation criteria are met.
|
Podáno IV
Ostatní jména:
Podáno IV
|
Experimentální: Part A cohort 3 Olaratumab + Doxorubicin
20 mg/kg loading dose of olaratumab administered IV on Day 1 and Day 8 in Cycle 1, followed by 15 mg/kg IV on Day 1 and Day 8 in subsequent cycles, and 75 mg/m2 of doxorubicin administered IV on Day 1 of every 21 day-cycle up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles.
Participants may continue to receive treatment until discontinuation criteria are met.
|
Podáno IV
Ostatní jména:
Podáno IV
|
Experimentální: Part B: Olaratumab
15 mg/kg olaratumab administered IV on Day 1 and Day 8 of every 21-day cycle.
Participants may continue to receive treatment until discontinuation criteria are met.
|
Podáno IV
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Part A: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Časové okno: Baseline to Study completion (Up To 3.5 Years)
|
Clinically significant events were defined as serious adverse events (SAE).
A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
|
Baseline to Study completion (Up To 3.5 Years)
|
Part A: Number of Participants With Dose Limiting Toxicities (DLTs)
Časové okno: Cycle 1 (21 Days)
|
DLT is defined as adverse event (AE) during Cycle 1 (Days 1 through 21) that was possibly related to the study drug and toxicities considered by the investigator as dose limiting.
A summary of other nonserious AEs, and all serious adverse events (SAE's), regardless of causality, is located in the Reported Adverse Events section.
|
Cycle 1 (21 Days)
|
Part B: Pharmacokinetics: Maximum Observed Concentration (Cmax) of Olaratumab
Časové okno: Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
Maximum observed serum concentration (Cmax) of olaratumab is reported.
|
Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
Part B: Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of Olaratumab
Časové okno: Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
AUC(0-t) hours (h), area under the serum concentration versus time curve from time zero to t hours at AUC(0-168h) for Cycle 1 Day 1 and Cycle 3 Day 1, AUC(0-336h) for Cycle 1 Day 8 and Cycle 3 Day 8 of Olaratumab is reported.
|
Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Part A: Pharmacokinetics: Maximum Observed Concentration (Cmax) of Olaratumab
Časové okno: Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1.5, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
Maximum observed serum concentration (Cmax) of olaratumab is reported.
|
Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1.5, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
Part A: Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of Olaratumab
Časové okno: Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1.5, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
AUC(0-t) hours (h), area under the serum concentration versus time curve from time zero to t hours at AUC(0-168h) for Cycle 1 Day 1 and Cycle 3 Day 1, AUC(0-336h) for Cycle 1 Day 8 and Cycle 3 Day 8 of Olaratumab is reported.
|
Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1.5, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
Part A: Pharmacokinetics: Maximum Observed Concentration (Cmax) of Doxorubicin
Časové okno: Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 3, Cycle 3 Day 1, Cycle 3 Day 2 and Cycle 3 Day 3: Immediately postinfusion
|
Maximum observed plasma concentration (Cmax) of doxorubicin is reported.
|
Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 3, Cycle 3 Day 1, Cycle 3 Day 2 and Cycle 3 Day 3: Immediately postinfusion
|
Part A: Pharmacokinetics: Maximum Observed Concentration (Cmax) of Doxorubicin
Časové okno: Cycle 1 Day 1 and Cycle 3 Day 1: Immediately postinfusion, 0.5, 1, 2, 4, 8, 24, 48, and 72 h postinfusion
|
Maximum observed plasma concentration (Cmax) of doxorubicin is reported.
|
Cycle 1 Day 1 and Cycle 3 Day 1: Immediately postinfusion, 0.5, 1, 2, 4, 8, 24, 48, and 72 h postinfusion
|
Part A: Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of Doxorubicin
Časové okno: Cycle 1 Day 1 and Cycle 3 Day 1: Immediately postinfusion, 0.5, 1, 2, 4, 8, 24, 48, and 72 h postinfusion
|
Area under the concentration verses time curve from zero to infinity (AUC[0-∞]) of doxorubicin is reported.
|
Cycle 1 Day 1 and Cycle 3 Day 1: Immediately postinfusion, 0.5, 1, 2, 4, 8, 24, 48, and 72 h postinfusion
|
Change From Baseline in Percentage of Participants With a Tumor Response
Časové okno: Baseline to Study completion (Up To 3.5 Years)
|
Tumor response was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1.
Complete Response (CR) is disappearance of all target lesions; Partial Response (PR) is greater than or equal to (≥) 30% decrease in sum of longest diameter of target lesions.
|
Baseline to Study completion (Up To 3.5 Years)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 15678
- I5B-JE-JGDK (Jiný identifikátor: Eli Lilly and Company)
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Olaratumab
-
Eli Lilly and CompanyUkončenoGastrointestinální stromální nádor (GIST)Spojené státy, Belgie, Německo, Holandsko, Polsko, Španělsko
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Eli Lilly and CompanyDokončenoMultiformní glioblastom u dospělýchSpojené státy
-
Eli Lilly and CompanyDokončenoSolidní nádorySpojené státy
-
Grupo Espanol de Investigacion en SarcomasAktivní, ne nábor
-
Eli Lilly and CompanyDostupnýSarkom měkkých tkáníKanada, Itálie, Korejská republika, Španělsko, Tchaj-wan, Spojené státy, Rakousko, Brazílie, Maďarsko, Indie, Spojené království
-
Eli Lilly and CompanyDokončenoMetastáza | MalignitaJaponsko
-
Eli Lilly and CompanyMerck Sharp & Dohme LLCDokončenoSarkom měkkých tkáníSpojené státy, Belgie, Dánsko, Francie
-
Eli Lilly and CompanyDokončenoSarkom, měkká tkáňSpojené státy
-
OctapharmaDokončeno
-
Eli Lilly and CompanyAktivní, ne náborSarkom měkkých tkáníSpojené státy, Španělsko, Francie, Korejská republika, Tchaj-wan, Japonsko, Holandsko, Austrálie, Maďarsko, Belgie, Itálie, Švýcarsko, Německo, Dánsko, Izrael, Spojené království, Kanada, Mexiko, Ruská Federace, Rakousko, Argentina, Polsk... a více